Outpatient 131I-rituximab radioimmunotherapy for non-Hodgkin lymphoma: A study in safety

Clinical Nuclear Medicine

Volumn 37, Issue 8, 2012, Pages 732-737

  Calais, Phillipe J ^a   Turner, John Harvey ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

nuclear oncology; outpatient; radiation protection; radioimmunotherapy lymphoma

Indexed keywords

RITUXIMAB; RITUXIMAB I 131; UNCLASSIFIED DRUG; 131I RITUXIMAB; 131I-RITUXIMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CAREGIVER; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; OUTPATIENT; RADIATION DOSE; RADIATION EXPOSURE; RADIATION SAFETY; RADIOIMMUNOTHERAPY; THERMOLUMINESCENCE; WHOLE BODY RADIATION; FAMILY; HALF LIFE TIME; MIDDLE AGED; RADIATION RESPONSE; TIME; URINE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CAREGIVERS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FAMILY; HALF-LIFE; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; OUTPATIENTS; RADIOIMMUNOTHERAPY; TIME FACTORS; WHOLE-BODY IRRADIATION;

EID: 84863864639     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31825ae6f6     Document Type: Article

References (33)

1. National Program of Cancer Registries (NPCR). Available at: http://apps.nccd. cdc.gov/uscs/toptencancers.aspx. Accessed October 14, 2011.
2. Tay K, Tai D, Tao M, et al. Relevance of the international prognostic index in the rituximab era. J Clin Oncol. 2011;29:e14.
3. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Study Group. Blood. 2005;106:3725-3732. (Pubitemid 41742196)
4. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced stage, follicular grade I non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005;23:1103-1108. (Pubitemid 46202265)
5. 131I-rituximab in routine clinical practice: 10-year singleinstitution experience of 142 consecutive patients. Blood. 2011;117:45-52.
6. Cheson BD. Time to remember to forget dose-intensification in lymphoma. J Clin Oncol. 2011;30:3954-3956.
7. Willegaignon J, Sapienza M, Ono C, et al. Outpatient radioiodine therapy for thyroid cancer. Clin Nucl Med. 2011;36:440-445.
8. Marriott CJ, Webber CE, Gulenchyn KY. Radiation exposure for 'caregivers'during high-dose outpatient radioiodine therapy. Radiat Prot Dosimetry. 2007; 123:62-67.
9. 131I) therapy for thyroid carcinoma. JAMA. 2000;283: 2272-2274.
10. International Commission on Radiological Protection. Release of patients after therapy with unsealed radionuclides. ICRP Publication 94. Ann. ICRP. 2004;34 (2).
11. Nuclear Regulatory Commission. Criteria for the Release of Individual Administered Radioactive Materials, 10 CFR Part 20 and 35: 62 FR 4120.Washington, DC: US Nuclear Regulatory Commission; 1997.
12. International Atomic Energy Agency. Release of Patients after Radionuclide Therapy. Vienna, Austria: International Atomic Energy Agency; 2009.
13. Australian Radiation Protection and Nuclear Safety Agency. Discharge of Patients Undergoing Treatment with Radioactive Substances. Radiation Protection Series No. 4. ARPANSA; 2002.
14. 131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkin lymphoma: a phase II clinical trial of a non-myeloablative dose regimen of chimeric rituximab radiolabelled in a hospital. Cancer Biother Radiopharm. 2003;18:513-524.
15. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
16. 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood. 2009;113: 1412-1421.
17. US Nuclear Regulatory Commission. Release of Patients Administered Radioactive Materials. Washington, DC: US Nuclear Regulatory Commission; 1997. Regulatory Guide 8.39.
18. Siegel JA. Revised nuclear regulatory commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy. J Nucl Med. 1998;39:28S-33S. (Pubitemid 28371373)
19. Harolds JA. New scrutiny of outpatient therapy with I-131. Clin Nucl Med. 2011;36:206-208.
20. Siegel JA, Marcus CS, Stabin MG. Licensee over-reliance on conservatisms in NRC guidance regarding the release of patients treated with I-131. Health Phys. 2007;93:667-677. (Pubitemid 350098504)
21. Tuttle WK, Brown PH. Applying nuclear regulatory commission guidelines to the release of patients treated with sodium iodine-131. J Nucl Med Technol. 2000;28:275-279. (Pubitemid 32039165)
22. 131I for thyroid cancer. J Nucl Med Technol. 2005;33:28-30.
23. Harbert JC, Wells N. Radiation exposure to the families of radioactive patients. J Nucl Med. 1974;15:887-888.
24. Jacobson AP, Plato A, Toeroek D. Contamination of the home environment by patients treated with iodine-131: initial results. Am J Public Health. 1978;68: 225-23.
25. Pant GS, Sharma SK, Bal CS, et al. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I. Radiat Prot Dosimetry. 2006;118:22-27. (Pubitemid 43786724)
26. 131I-anti- B1 antibody: radiation exposure to family members. J Nucl Med. 2001;42: 907-915.
27. Rutar FJ, Augustine SC, Kaminski MS, et al. Feasibility and safety of outpatient Bexxar® therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Clin Lymphoma. 2001;2:164-172. (Pubitemid 34092722)
28. DGE (NSCP). Radiation Protection 97 - Radiation Protection Following Iodine-131 Therapy. Brussels, Belgium: European Commission;1998.
29. 131I after radioiodine therapy: measurements in exhaled air. Eur J Nucl Med Mol Imaging. 2011;38:2165-2172.
30. Brans B, Van Den Eynde F, Audenaert K, et al. Depression and anxiety during isolation and radionuclide therapy. Nucl Med Commun. 2003;24:881-886.
31. Higashi T, Nishii R, Yamada S, et al. Delayed initial radioactive iodine therapy results in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med. 2011;52: 683-689.
32. 131I therapy. J Nucl Med. 2011;52:681-682.
33. 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011;21:335-355.